Study Shows 16% of Patients Return to Humira After Biosimilar Switch
Question
Study Shows 16% of Patients Return to Humira After Biosimilar Switch
Direct answer
Product stickiness and 're-switching' behavior mitigate the impact of patent cliffs on pharmaceutical revenue. — bullish pressure on ABBV via revenue durability via patient stickiness.
- Original publisher
- Market Ontology
- Evidence through
- 2026-06-29
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Study Shows 16% of Patients Return to Humira After Biosimilar Switch”, revision 1, evidence through 2026-06-29. https://marketontology.com/catalysts/2026-06-29/study-shows-16-of-patients-return-to-humira-after-biosimilar-switch-a26cb8
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| ABBV | ▲Bull | 1–4 weeks | revenue durability via patient stickiness | 50 |
Study Shows 16% of Patients Return to Humira After Biosimilar Switch
Product stickiness and 're-switching' behavior mitigate the impact of patent cliffs on pharmaceutical revenue. — bullish pressure on ABBV via revenue durability via patient stickiness.
16% of patients return to Humira after switching to biosimilars
- Source16% of patients return to Humira after switching to biosimilars
- TransmissionProduct stickiness and 're-switching' behavior mitigate the impact of patent cliffs on pharmaceutical revenue.
- SummaryHumira's revenue erosion may be slower than expected. Patient 're-switching' provides a tailwind for AbbVie. AbbVie's valuation remains below the S&P 500 average despite the 52-week high.
- ABBVDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- ABBV closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- ABBV price vs. pre-event level
- ABBV volume vs. 20-day average
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- New study examines real-world switching patterns after patients transition from Humira to biosimilars · news · 2026-06-29
Related catalysts
- 2026-10-19Citadel Expands Defensive Healthcare Positions Across AbbVie, Abbott, and Eli LillyABBV ABT LLY
- 2026-10-19Citadel Expands Defensive Healthcare Positions Across AbbVie, Abbott, and Eli LillyABBV ABT LLY SPY
- 2026-10-13Abbott and AbbVie Gain Over 1.6% Outperforming S&P on Strong Q3 Growth OutlookABBV ABT
- 2026-10-13Abbott and AbbVie Gain Over 1.6% Outperforming S&P on Strong Q3 Growth OutlookABBV ABT
- 2026-10-13Abbott and AbbVie Gain Over 1.6% Outperforming S&P on Strong Q3 Growth OutlookABBV ABT
- 2026-09-21Bristol Myers Squibb Growth Portfolio Reaches 60% of Revenue Following 153% EPS SurgeABBV BMY
- 2026-09-21Bristol Myers Squibb growth portfolio hits 60% of revenue after Q2 profit surgeABBV BMY
- 2026-09-21Bristol Myers Squibb growth portfolio reaches 60% of revenue following Q2 EPS surgeABBV BMY
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.